iSpecimen Inc. Cost of Revenue
iSpecimen Inc. (ISPC) reported Cost of Revenue of $83.29 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-14
- iSpecimen Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $83.29K, a 81.25% decline year-over-year.
- iSpecimen Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $84.41K, a 87.16% decline year-over-year.
- iSpecimen Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $598.84K, a 54.78% decline year-over-year.
- iSpecimen Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $204.59K, a 86.84% decline year-over-year.
- iSpecimen Inc. cost of goods and services sold for fiscal 2025 was $1.90M, a 64.08% decline from fiscal 2024.
- iSpecimen Inc. cost of goods and services sold for fiscal 2024 was $5.30M, a 10.01% increase from fiscal 2023.
- iSpecimen Inc. cost of goods and services sold for fiscal 2023 was $4.82M, a 1.33% increase from fiscal 2022.
- iSpecimen Inc. cost of goods and services sold for fiscal 2022 was $4.76M, a 9.37% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $83.29K 10-Q · filed 2026-08-14 | $167.70K 10-Q · filed 2026-08-14 | $766.54K derived: sum of 3 quarters · filed 2026-08-14 | $971.13K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $84.41K 10-Q · filed 2026-05-18 | $683.25K derived: sum of 2 quarters · filed 2026-05-18 | $887.84K derived: sum of 3 quarters · filed 2026-05-18 | $1.33M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $598.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $803.43K derived: sum of 2 quarters · filed 2026-04-01 | $1.25M derived: sum of 3 quarters · filed 2026-08-14 | $1.90M 10-K · filed 2026-04-01 |
| 2025-09-30 | $204.59K 10-Q · filed 2025-11-17 | $648.77K derived: sum of 2 quarters · filed 2026-08-14 | $1.31M 10-Q · filed 2025-11-17 | $2.63M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $444.18K 10-Q · filed 2026-08-14 | $1.10M 10-Q · filed 2026-08-14 | $2.43M derived: sum of 3 quarters · filed 2026-08-14 | $3.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $657.28K 10-Q · filed 2026-05-18 | $1.98M derived: sum of 2 quarters · filed 2026-05-18 | $3.54M derived: sum of 3 quarters · filed 2026-05-18 | $4.96M derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $2.88M derived: sum of 2 quarters · filed 2026-04-01 | $4.30M derived: sum of 3 quarters · filed 2026-04-01 | $5.30M 10-K · filed 2026-04-01 |
| 2024-09-30 | $1.55M 10-Q · filed 2025-11-17 | $2.98M derived: sum of 2 quarters · filed 2025-11-17 | $3.98M 10-Q · filed 2025-11-17 | $5.41M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | $1.42M 10-Q · filed 2025-08-14 | $2.42M 10-Q · filed 2025-08-14 | $3.85M derived: sum of 3 quarters · filed 2025-08-14 | $5.24M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.00M 10-Q · filed 2025-05-19 | $2.43M derived: sum of 2 quarters · filed 2025-05-19 | $3.82M derived: sum of 3 quarters · filed 2025-05-19 | $4.67M derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | $2.82M derived: sum of 2 quarters · filed 2025-04-14 | $3.67M derived: sum of 3 quarters · filed 2025-04-14 | $4.82M 10-K · filed 2025-04-14 |
| 2023-09-30 | $1.39M 10-Q · filed 2024-11-07 | $2.25M derived: sum of 2 quarters · filed 2024-11-07 | $3.39M 10-Q · filed 2024-11-07 | $4.80M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $853.63K 10-Q · filed 2024-08-06 | $2.00M 10-Q · filed 2024-08-06 | $3.41M derived: sum of 3 quarters · filed 2024-08-06 | $4.59M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.15M 10-Q · filed 2024-05-07 | $2.56M derived: sum of 2 quarters · filed 2024-05-07 | $3.74M derived: sum of 3 quarters · filed 2024-05-07 | $4.74M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $2.59M derived: sum of 2 quarters · filed 2024-03-13 | $3.59M derived: sum of 3 quarters · filed 2024-03-13 | $4.76M 10-K · filed 2024-03-13 |
| 2022-09-30 | $1.18M 10-Q · filed 2023-11-02 | $2.18M derived: sum of 2 quarters · filed 2023-11-02 | $3.35M 10-Q · filed 2023-11-02 | $4.57M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $999.74K 10-Q · filed 2023-08-02 | $2.17M 10-Q · filed 2023-08-02 | $3.39M derived: sum of 3 quarters · filed 2023-08-02 | $4.30M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $1.17M 10-Q · filed 2023-05-04 | $2.39M derived: sum of 2 quarters · filed 2023-05-04 | $3.30M derived: sum of 3 quarters · filed 2023-05-04 | $4.79M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.22M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $2.14M derived: sum of 2 quarters · filed 2023-03-30 | $3.63M derived: sum of 3 quarters · filed 2023-03-30 | $5.25M 10-K/A · filed 2023-03-30 |
| 2021-09-30 | $913.83K 10-Q · filed 2022-11-08 | $2.40M derived: sum of 2 quarters · filed 2022-11-08 | $4.03M 10-Q · filed 2022-11-08 | $5.58M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $1.49M 10-Q · filed 2022-08-04 | $3.11M 10-Q · filed 2022-08-04 | $4.67M derived: sum of 3 quarters · filed 2022-08-04 | $5.57M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $1.62M 10-Q · filed 2022-05-10 | $3.18M derived: sum of 2 quarters · filed 2022-05-10 | $4.08M derived: sum of 3 quarters · filed 2022-05-10 | $4.55M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $2.46M derived: sum of 2 quarters · filed 2022-03-22 | $2.93M derived: sum of 3 quarters · filed 2022-03-22 | $3.59M 10-K · filed 2022-03-22 |
| 2020-09-30 | $903.86K 10-Q · filed 2021-11-04 | $1.38M derived: sum of 2 quarters · filed 2021-11-04 | $2.03M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $473.98K 10-Q · filed 2021-08-10 | $1.13M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |